Publications by authors named "Lilly Zhang"

Claim this Profile
O
Optimization of mTOR Inhibitors Using Property-Based Drug Design and Free-Wilson Analysis for Improved In Vivo Efficacy.
Sean T Murphy, Joy Atienza, Jason W Brown, Zacharia S Cheruvallath, Matthew J Cukierski, Lilly Zhang

ACS Med Chem Lett· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Persistence Pays Off: Live Birth after Uterus Transplant, Overcoming Recurrent Pregnancy Loss with Cerclage Placement.
Liza Johannesson, Sophie Anderson, J Michael Putman, Robert T Gunby, Lilly Zhang

J Clin Med· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neonatal Outcomes after Uterus Transplantation: Dallas Uterus Transplant Study.
Jackie R York, Giuliano Testa, Robert T Gunby, J Michael Putman, Gregory J McKenna, Lilly Zhang

Am J Perinatol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical pregnancy rates and experience with in vitro fertilization after uterus transplantation: Dallas Uterus Transplant Study.
J Michael Putman, Lilly Zhang, Anthony R Gregg, Giuliano Testa, Liza Johannesson

Am J Obstet Gynecol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Twelve Live Births After Uterus Transplantation in the Dallas UtErus Transplant Study.
Liza Johannesson, Giuliano Testa, J Michael Putman, Gregory J McKenna, E Colin Koon, Lilly Zhang

Obstet Gynecol· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rational discovery of a highly novel and selective mTOR inhibitor.
Stanley Jin, Satoshi Mikami, Nick Scorah, Young Chen, Petro Halkowycz, Lilly Zhang

Bioorg Med Chem Lett· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-based design and SAR development of 5,6-dihydroimidazolo[1,5-f]pteridine derivatives as novel Polo-like kinase-1 inhibitors.
Andre Kiryanov, Srinivasa Natala, Benjamin Jones, Christopher McBride, Victoria Feher, Lilly Zhang

Bioorg Med Chem Lett· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of TAK-960: an orally available small molecule inhibitor of polo-like kinase 1 (PLK1).
Zhe Nie, Victoria Feher, Srinivasa Natala, Christopher McBride, Andre Kiryanov, Lilly Zhang

Bioorg Med Chem Lett· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biological characterization of TAK-901, an investigational, novel, multitargeted Aurora B kinase inhibitor.
Pamela Farrell, Lihong Shi, Jennifer Matuszkiewicz, Deepika Balakrishna, Takashi Hoshino, Lilly Zhang

Mol Cancer Ther· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and synthesis of orally available MEK inhibitors with potent in vivo antitumor efficacy.
Mark E Adams, Michael B Wallace, Toufike Kanouni, Nicholas Scorah, Shawn M O'Connell, Lilly Zhang

Bioorg Med Chem Lett· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TAK-960, a novel, orally available, selective inhibitor of polo-like kinase 1, shows broad-spectrum preclinical antitumor activity in multiple dosing regimens.
Yuichi Hikichi, Kohei Honda, Kouki Hikami, Hitoshi Miyashita, Isao Kaieda, Lilly Zhang

Mol Cancer Ther· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis